UB Paderborn / Katalog / Suche / in CDI

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma

Nature medicine, 2016-03, Vol.22 (3), p.278-287

2016

Link zum Volltext

Verfügbarkeit prüfen

Titin isoform switch in ischemic human heart disease

Circulation (New York, N.Y.), 2002-09, Vol.106 (11), p.1333-1341

2002

Link zum Volltext

Verfügbarkeit prüfen

Unfolding of Titin Domains Explains the Viscoelastic Behavior of Skeletal Myofibrils

Biophysical journal, 2001-03, Vol.80 (3), p.1442-1451

2001

Link zum Volltext

Verfügbarkeit prüfen

Damped Elastic Recoil of the Titin Spring in Myofibrils of Human Myocardium

Proceedings of the National Academy of Sciences - PNAS, 2003-10, Vol.100 (22), p.12688-12693

2003

Link zum Volltext

Verfügbarkeit prüfen

Abstract 910: Amanitin-based ADCs targeting PSMA as novel therapeutic modality for prostate cancer therapy

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.910-910

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 915: Preclinical evaluation of anti-CD37 antibody-targeted amanitin conjugates (ATAC) in B-cell malignancies

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.915-915

2021

Link zum Volltext

Verfügbarkeit prüfen

A First in Human Study Planned to Evaluate Hdp-101, an Anti-BCMA Amanitin Antibody-Drug Conjugate with a New Payload and a New Mode of Action, in Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.34-34

2020

Link zum Volltext

Verfügbarkeit prüfen

HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells

Molecular cancer therapeutics, 2021-02, Vol.20 (2), p.367-378

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 237: Preclinical evaluation of anti-HER2 Antibody Targeted Amanitin Conjugates (ATACs) on HER2low breast cancer with chromosome 17p deletion

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.237-237

2019

Link zum Volltext

Verfügbarkeit prüfen

Anti-CD37 Alpha-Amanitin Conjugated Antibodies As Therapeutic Weapons for Richter's Syndrome

Blood, 2021-11, Vol.138 (Supplement 1), p.791-791

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-10-19: Precise targeting of POLR2A for treating triple negative breast cancer with Chr17p loss

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P3-P3-10-19

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 921: Combination of antibody-targeted amanitin conjugates (ATAC) with immune checkpoint inhibitors shows synergistic therapeutic effect in vitro and in vivo

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.921-921

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2973: CD269 - A promising target for amanitin based ADCs

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2973-2973

2016

Link zum Volltext

Verfügbarkeit prüfen

Anti-CD37 α-amanitin–conjugated antibodies as potential therapeutic weapons for Richter syndrome

Blood, 2022-09, Vol.140 (13), p.1565-1569

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeted immunotherapy for HER2-low breast cancer with 17p loss

Science translational medicine, 2021-02, Vol.13 (580)

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 740: Preclinical evaluation of an anti-PSMA antibody-targeted amanitin conjugate (ATAC)

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.740-740

2018

Link zum Volltext

Verfügbarkeit prüfen

Titin-based contribution to shortening velocity of rabbit skeletal myofibrils

The Journal of physiology, 2002-04, Vol.540 (1), p.177-188

2002

Link zum Volltext

Verfügbarkeit prüfen

Abstract 62: CD19 - a potential target for Amanitin-based ADCs

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.62-62

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 77: Preclinical evaluation of HDP-101, an anti-BCMA antibody-drug conjugate

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.77-77

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 735: SAR of amanitin and optimization of linker-amanitin derivatives for solid tumors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.735-735

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2636: Amanitin-based ADCs targeting Guanylyl cyclase C (GCC) as novel therapeutic modality for treatment of colorectal cancer

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2636-2636

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1523: Subcutaneous dosing of amatoxin-based ADCs increases the therapeutic index

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1523-1523

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-106: Overcoming limitations of current Antibody-Drug Conjugates (ADCs) by a novel linker technology

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.LB-106-LB-106

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 664: Amanitin-based antibody-drug conjugates targeting the prostate-specific membrane antigen

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.664-664

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1754: Amatoxin-based antibody-drug conjugates induce immunogenic cell death and improve the anti-tumor efficacy of immune checkpoint inhibitors in humanized mouse models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1754-1754

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma

Titin isoform switch in ischemic human heart disease

Unfolding of Titin Domains Explains the Viscoelastic Behavior of Skeletal Myofibrils

Damped Elastic Recoil of the Titin Spring in Myofibrils of Human Myocardium

Abstract 910: Amanitin-based ADCs targeting PSMA as novel therapeutic modality for prostate cancer therapy

Abstract 915: Preclinical evaluation of anti-CD37 antibody-targeted amanitin conjugates (ATAC) in B-cell malignancies

A First in Human Study Planned to Evaluate Hdp-101, an Anti-BCMA Amanitin Antibody-Drug Conjugate with a New Payload and a New Mode of Action, in Multiple Myeloma

HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells

Abstract 237: Preclinical evaluation of anti-HER2 Antibody Targeted Amanitin Conjugates (ATACs) on HER2low breast cancer with chromosome 17p deletion

Anti-CD37 Alpha-Amanitin Conjugated Antibodies As Therapeutic Weapons for Richter's Syndrome

Abstract P3-10-19: Precise targeting of POLR2A for treating triple negative breast cancer with Chr17p loss

Abstract 921: Combination of antibody-targeted amanitin conjugates (ATAC) with immune checkpoint inhibitors shows synergistic therapeutic effect in vitro and in vivo

Abstract 2973: CD269 - A promising target for amanitin based ADCs

Anti-CD37 α-amanitin–conjugated antibodies as potential therapeutic weapons for Richter syndrome

Targeted immunotherapy for HER2-low breast cancer with 17p loss

Abstract 740: Preclinical evaluation of an anti-PSMA antibody-targeted amanitin conjugate (ATAC)

Titin-based contribution to shortening velocity of rabbit skeletal myofibrils

Abstract 62: CD19 - a potential target for Amanitin-based ADCs

Abstract 77: Preclinical evaluation of HDP-101, an anti-BCMA antibody-drug conjugate

Abstract 735: SAR of amanitin and optimization of linker-amanitin derivatives for solid tumors

Abstract 2636: Amanitin-based ADCs targeting Guanylyl cyclase C (GCC) as novel therapeutic modality for treatment of colorectal cancer

Abstract 1523: Subcutaneous dosing of amatoxin-based ADCs increases the therapeutic index

Abstract LB-106: Overcoming limitations of current Antibody-Drug Conjugates (ADCs) by a novel linker technology

Abstract 664: Amanitin-based antibody-drug conjugates targeting the prostate-specific membrane antigen

Abstract 1754: Amatoxin-based antibody-drug conjugates induce immunogenic cell death and improve the anti-tumor efficacy of immune checkpoint inhibitors in humanized mouse models

Suchergebnisse filtern